RxDoctor Payments Data

Michael Dorman, MD

Dermatology · West Bloomfield, MINPI 1841281532

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $319,375 of the $433,272 with a category attached, or 73.7%. It is spread thinly across 45 manufacturers, the largest accounting for just 23.7%. 2025 is the largest year on record at $112,768, 3.4 times the $32,740 reported in 2019. Among dermatology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$433,272in general payments, 2019–2025

Across 1,425 payments — averaging $304.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$103K
  • Dermavant Sciences, Inc.$65K
  • UCB, Inc.$50K
  • Johnson & Johnson$49K
  • Arcutis Biotherapeutics, Inc.$40K
  • Janssen Scientific Affairs, LLC$37K
  • plus $90K from 39 others

What the payments were for

  • Consulting fees$56,71013%
  • Speaking & faculty fees$319,37574%
  • Travel & lodging$21,3685%
  • Food & beverage$35,2818%
  • Education$5370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$433,272 in reported general payments places this provider in the 95th percentile of 404 dermatology providers in Michigan.

See all dermatology providers in Michigan

Medicare billing

Part B allowed, 2024
$406,656
Medicare patients
1,244
Services billed
5,950

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab13$176,273
Dupixent PenDupilumab46$167,971
EnbrelEtanercept12$44,904
Betamethasone Dipropionate144$6,243
Ketoconazole341$6,090
Triamcinolone Acetonide490$5,697
Ciclopirox146$5,577
Pimecrolimus18$5,080
Azelaic Acid39$4,953
Tacrolimus39$3,915
Metronidazole104$3,848
Mometasone Furoate143$2,497
Acitretin11$2,345
Ammonium Lactate167$2,124
Clindamycin Phosphate72$2,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$49,118$176,27313 claims
AmgenEnbrel$2,956$44,90412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 dermatology providers in Michigan.

Other dermatology in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →